This is a StreetInsider.com Premium Only Page

Omeros (OMER) – Analyst EPS Change

May 18, 2022 07:43 AM Omeros Corp's (OMER) Narsoplimab Approval Pathway is More Challenging, PT Lowered to $12 at BofA Securities

Jun 13, 2017 12:39 PM Cantor Fitzgerald Maintains Neutral & $15 PT on Omeros (OMER) Following 'Breakthrough Therapy Designation Provides Validation for OMS721 in IgA Nephropathy'

Mar 20, 2017 06:48 AM

Mar 17, 2017 07:54 AM

Mar 17, 2017 06:24 AM

Nov 10, 2016 07:04 AM

Nov 11, 2015 06:41 AM

Nov 10, 2015 02:18 PM